SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-22-002452
Filing Date
2022-11-14
Accepted
2022-11-14 16:30:56
Documents
4
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 10670
2 QUARTERLY REPORT nymox_ex991.htm EX-99.1 427115
3 CEO CERTIFICATION nymox_ex992.htm EX-99.2 16559
4 CFO CERTIFICATION nymox_ex993.htm EX-99.3 16213
  Complete submission text file 0001640334-22-002452.txt   471602
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 221386381
SIC: 2835 In Vitro & In Vivo Diagnostic Substances